文献速递造血干细胞移植与细胞治疗

疾病风险合并症指数对异基因造血干细胞移植后总生存的预测价值

Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

研究在明尼苏达大学对2000至2013年接受异基因造血干细胞移植的959例成人血液恶性肿瘤患者进行移植前疾病风险合并症指数(DRCI)评分,将患者分为6个风险组,2年总生存率从极低危组的74%至极高危组的34%。校正年龄和供者类型后,DRCI评分升高与总死亡风险独立增加相关,并独立预测复发、无病生存和移植物抗宿主病无复发生存。

要点

  • 移植前DRCI评分将患者分为6个风险组,2年总生存率从极低危组74%至极高危组34%。
  • 校正年龄和供者类型后,总死亡风险随DRCI评分升高而独立增加。
  • DRCI评分还独立预测复发风险、无病生存和移植物抗宿主病无复发生存。

核心结论

  • 移植前DRCI评分系统可预测异基因造血干细胞移植后的结局,可用于指导考虑移植患者的临床决策。

研究设计与样本

  • 在明尼苏达大学对2000年至2013年接受异基因造血干细胞移植的959例成人血液恶性肿瘤患者进行移植前DRCI评分的前瞻性观察性研究。

主要发现

  • DRCI评分将患者分为6个风险组,2年总生存率从极低危DRCI组的74%至极高危DRCI组的34%。
  • 在校正患者年龄和供者类型的多元回归分析中,总死亡风险随DRCI评分升高而独立增加。
  • DRCI评分独立预测复发风险、无病生存和移植物抗宿主病无复发生存。

临床怎么用

  • 作者认为移植前DRCI评分系统可预测异基因造血干细胞移植后的结局,可用于指导考虑移植患者的临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematologic cell transplantation (alloHCT) is the only curative therapy for many adults with hematological malignancies. However, it can be associated with substantial risks of morbidity and mortality that are dependent on patient comorbidity- or disease risk-related factors. Several pretransplantation prognostic scoring systems have been developed to estimate survival of patients undergoing alloHCT; however, there is significant interstudy variability in the predictive capacity of these assessment tools. We tested the prognostic capability of a composite scoring system including the disease risk index and HCT comorbidity index (DRCI). The DRCI scoring system was applied pretransplantation to determine whether it predicted clinical outcomes of 959 adult patients with hematological malignancies undergoing alloHCT from 2000 to 2013 at the University of Minnesota. The DRCI score categorized patients into 6 risk groups, with 2-year overall survival ranging between 74% for the very low-risk DRCI group and 34% for the very high-risk DRCI group. In multiple regression analyses adjusted for patient age and donor type, the risk of overall mortality independently increased as the DRCI score increased. Additionally, the DRCI score independently predicted risk of relapse, disease-free survival, and graft-versus-host disease-free/relapse-free survival. Our data demonstrate that the pretransplantation DRCI scoring system predicts outcomes after alloHCT and can be used to guide clinical decision making for patients considering alloHCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bejanyan N, Brunstein CG, Cao Q, et al. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv. 2019. PMID: 30674457. doi:10.1182/bloodadvances.2018018549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。